President Trump’s most-favored-nation pricing initiative for prescription drugs is reshaping global pharmaceutical markets – so far, the EU competition law implications have received little attention. This article aims to fill the gap. It examines how the MFN framework, by benchmarking U.S. prices against European prices, creates tangible risks for pharmaceutical companies under both Article 101 and Article 102 TFEU. Manufacturers responding to Washington’s pressure through coordin
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 18.97.9.171
Please verify email or join us to access premium content!